Putting the immune system in control
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after standard of care therapy to delay or prevent disease recurrence. Relapse vaccines are aimed at improving survival by putting the patient’s immune system back in control while tumor burden is low, and the immune system is in relatively good shape.
A growing pipeline of relapse vaccines
Our lead product DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse. DCP-001 is currently being evaluated in a Phase II clinical trial in acute myeloid leukemia (AML). We are pursuing similar vaccination approaches in other malignancies, including solid tumors.
Company
Pipeline
Science
Collaborations
Latest News
DCprime Presents Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting
Phase II Data for DCprime’s Cell-based Cancer Relapse Vaccine Shows the Potential to Successfully Control Residual Disease as the Basis for a Prolonged Remission in AML Leiden, The Netherlands, December 7, 2020 – DCprime, the front-runner in the field of relapse vaccines, published interim results from its ongoing Phase
DCprime Presents Preclinical Data at SITC 2020 Validating the Use of its Cell-based Cancer Relapse Vaccine in Ovarian Cancer
Results demonstrate that the company’s lead vaccine candidate can direct a comprehensive immune response against ovarian tumor cells and induce the formation of memory T cells Leiden, The Netherlands, November 9, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical results
DCprime to Present Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting
Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH Annual Meeting and Exposition on December 5, 2020. The
Latest News
- DCprime Presents Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting 7 December, 2020Phase II Data for DCprime’s Cell-based Cancer Relapse Vaccine Shows the Potential to Successfully Control Residual Disease as the Basis for a Prolonged Remission in AML Leiden, The Netherlands, December 7, 2020 – DCprime, the front-runner in the field of relapse vaccines, published interim results from its ongoing Phase II study (ADVANCE II, Clintrials.gov: NCT03697707) in …Read More
- DCprime Presents Preclinical Data at SITC 2020 Validating the Use of its Cell-based Cancer Relapse Vaccine in Ovarian Cancer 9 November, 2020Results demonstrate that the company’s lead vaccine candidate can direct a comprehensive immune response against ovarian tumor cells and induce the formation of memory T cells Leiden, The Netherlands, November 9, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical results at the virtual 35th Annual Meeting of …Read More
- DCprime to Present Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting 5 November, 2020Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH Annual Meeting and Exposition on December 5, 2020. The Interim data on both primary …Read More